Biocept,

Biocept, Inc. (Nasdaq: BIOC) develops and performs clinical laboratory tests to help patients with cancer that has metastasized to the central nervous system (CNS). Our CNSide™ assay provides enhanced detection and analysis of tumor cells and cell-free DNA from cerebrospinal fluid (CSF). Quantitative results help evaluate a patient’s response to treatment. Additional biomarkers can characterize genetic changes associated with therapy resistance and identify new options for treating CNS metastasis. CNSide results from Biocept’s CLIA-certified and CAP-accredited laboratory help oncologists manage one of the most difficult complications of cancer, answering three critical questions: Is there tumor in the CSF? Is there a target for treatment? Is there a trend in treatment response? The Biocept team is dedicated to improving care for cancer patients – which means making a difference in people’s lives, every day. Biocept also provides RT-PCR based COVID-19 testing to support state and national public health efforts.